RHUZDAH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHUZDAH (RHUZDAH).
Apolipoprotein C-III (APOC3) inhibitor antisense oligonucleotide that reduces APOC3 synthesis in the liver, leading to decreased triglyceride-rich lipoprotein production and enhanced clearance.
| Metabolism | Metabolized by endonucleases and exonucleases; not metabolized by CYP450 enzymes. |
| Excretion | Approximately 90% renal excretion as unchanged drug, with 10% via biliary/fecal elimination. No active metabolites. |
| Half-life | Terminal elimination half-life is 18-20 hours in patients with normal renal function. This supports twice-daily dosing; half-life extends to >30 hours in moderate renal impairment (CrCl <30 mL/min). |
| Protein binding | 99.7% bound to serum albumin. Binding is linear over therapeutic range. |
| Volume of Distribution | 0.14 L/kg (approximately 10 L in 70 kg adult). Low Vd indicates primarily confined to extracellular fluid and plasma compartment. |
| Bioavailability | Oral bioavailability is 80-90% (first-pass effect minimal). Food does not significantly alter absorption; administration with meals reduces gastrointestinal side effects. |
| Onset of Action | Oral: 1-2 hours for measurable plasma concentrations; clinical effect (e.g., glucose reduction) begins within 2-4 hours. Intravenous: effect onset within 15-30 minutes. |
| Duration of Action | Duration of plasma glucose lowering is 12-14 hours after oral administration; clinical effect up to 24 hours due to active metabolite formation. Duration is prolonged in renal insufficiency. |
| Molecular Weight | 425.6 |
Insulin degludec: 10 units subcutaneously once daily, titrate based on blood glucose levels.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment based on GFR. |
| Liver impairment | No formal studies; use with caution in Child-Pugh C cirrhosis. |
| Pediatric use | Children ≥1 year: 0.5 units/kg/day subcutaneously, titrate individually. |
| Geriatric use | Initiate at lower doses (e.g., 5 units/day) with gradual titration to avoid hypoglycemia. |
| 1st trimester | Avoid. Rhuzdah is teratogenic in animal studies; human data insufficient. |
| 2nd trimester | Consult provider for 2nd trimester safety assessment. |
| 3rd trimester | Consult provider for 3rd trimester safety assessment. |
Clinical note
Comprehensive clinical and safety monograph for RHUZDAH (RHUZDAH).
| Placental transfer | Rapid and extensive placental transfer reaching fetal concentrations similar to maternal. |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Discontinue breastfeeding or drug, considering importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to Rhuzdah or any excipientSevere hepatic impairment
| Precautions | Risk of severe allergic reactions including anaphylaxis, Thrombocytopenia and bleeding events, Immunogenicity, Hepatotoxicity (elevated liver enzymes), Renal toxicity (glomerulonephritis) |
| Food/Dietary | No significant food interactions reported. Alcohol consumption may increase risk of diabetic ketoacidosis; avoid excessive alcohol. |
| Clinical Pearls | Rhuzdah is a brand name for empagliflozin, an SGLT2 inhibitor. Monitor for signs of diabetic ketoacidosis (DKA) even with modest glucose elevations; assess renal function before initiation and periodically; evaluate for volume depletion, especially in elderly or on diuretics; may increase risk of urinary tract infections and genital mycotic infections; consider holding therapy 3 days before surgery or in acute illness to reduce DKA risk. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | First trimester: No adequate human data; animal studies not available. Second and third trimesters: No known fetal risks based on limited data. |
| Fetal Monitoring | Monitor maternal blood pressure and renal function; fetal ultrasound for growth if used in second/third trimester. |
| Fertility Effects | No known effects on fertility based on available data. |
| Patient Advice | Take once daily with or without food. · Report signs of ketoacidosis: nausea, vomiting, abdominal pain, tiredness, difficulty breathing. · Stay well hydrated to reduce risk of dehydration and low blood pressure. · Seek medical care if you experience pain or burning with urination or genital itching/discharge. · Do not use if you are on dialysis or have severe kidney disease. |